BioAlliance suspends liver cancer trial

Following advice from the Drug Safety Monitoring Board, BioAlliance has suspended a Phase II/III trial of doxorubicin Transdrug for liver cancer. The drug did show clinical activity; however, it also resulted in "frequent and more severe pulmonary adverse events than expected," according to BioAlliance. Release

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.